BRAF and colorectal cancer: In contrast, when used alone, these drugs produce only minimal benefits in BRAF-mutant colorectal cancer [14] because they cause reactivation of RAS (via a feedback mechanism) [15–17] or activation of signaling through the PI3K/AKT pathway [18].